StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Ayala Pharmaceuticals stock opened at $0.03 on Thursday. The stock has a market cap of $1.22 million, a P/E ratio of 0.00 and a beta of 1.63. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $1.49. The firm’s fifty day moving average price is $0.03 and its 200-day moving average price is $0.04.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.